Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Yahoo! Finance
This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 19.57%. A quarter ago, it was expected that this company would post a loss of $0.50 per share when it actually produced a loss of $0.38, delivering a surprise of 24%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Century Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.79 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 69.74%. This compares to year-ago revenues of $0.15 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Century Therapeutics shares
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion LeadersGlobeNewswire
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Piper Sandler from $12.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
IPSC
Earnings
- 5/9/24 - Beat
IPSC
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/5/25 - Form 4
- 2/5/25 - Form 4
- IPSC's page on the SEC website